Evidence map›Paper›PMID 31168022›Full record

ArticleBioscience trends2019

MLS128 antibody-induced suppression of colon cancer cell growth is mediated by a desmocollin and a 110 kDa glycoprotein.

Sarah C Shuck, Teresa Hong, Markus Kalkum, Ryo Igarashi, Kota Kajiya, John Termini, Kazuo Yamamoto, Yoko Fujita-Yamaguchi

Open access · diamondAbstract read
In one paragraph

Article in Bioscience trends, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Sarah C ShuckDepartment of Molecular Medicine, Beckman Research Institute.
Teresa HongDepartment of Molecular Imaging and Therapy, Beckman Research Institute.
Markus KalkumDepartment of Molecular Imaging and Therapy, Beckman Research Institute.
Ryo IgarashiDepartment of Molecular Medicine, Beckman Research Institute.
Kota KajiyaDepartment of Molecular Medicine, Beckman Research Institute.
John TerminiDepartment of Molecular Medicine, Beckman Research Institute.
Kazuo YamamotoDepartment of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo.
Yoko Fujita-YamaguchiDepartment of Diabetes Complications & Metabolism, Beckman Research Institute.
Beckman Research InstituteBeckman Laser Institute and Medical Clinic · USThe University of Tokyo · JP

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI STANLEY R. HAMILTON · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

Protein glycosylation is a diverse form of post-translational modification. Two to three consecutive O-linked N-acetylgalactosamines (Tn-antigens) are recognized by antibodies such as MLS128. MLS128 mAb inhibited cell growth and bound to a 110 kDa glycoprotein (GP) in LS180 and HT29 colon cancer cells. However, purification and identification of the 110 kDa GP was unsuccessful due to its low abundance. The present study used a highly sophisticated and sensitive mass spectrometry method to identify proteins immunoprecipitated with MLS128 and separated by two-dimensional gel electrophoresis. Three desmosome components were identified. Of these, desmocollin and desmoglein shared many similar characteristics, including molecular mass, pI, and potential Tn-antigen sites. Western blotting analyses of LS180 cell lysates revealed a common 110 kDa band recognized by MLS128 and anti-desmocollin, but not by anti-desmoglein. Immunofluorescence microscopy of LS180 cells revealed that desmocollin is membrane-bound, while desmoglein is primarily localized in the cytosol. Confocal microscopy demonstrated colocalization of the desmocollin-specific antibody with the MLS128 antibody on the cell membrane, suggesting that desmocollin may contain Tn-antigens recognized by MLS128. Treatment of LS180 cells with siRNA to knock down desmocollin expression or a desmocollin-specific antibody decreased cell viability, suggesting a critical role for this protein in cell growth and survival. N-glycosidase F digestion of the 110 kDa GP and desmocollin suggested that although both proteins contain N-glycosylation sites, they are not identical. These findings suggest that desmocollin colocalizes with the 110 kDa GP and that growth inhibition induced by the MLS128 antibody may be mediated through a mechanism that involves desmocollin.

Indexed as

Antibodies, MonoclonalAntigens, Tumor-Associated, CarbohydrateBlotting, WesternCell Line, TumorCell ProliferationColonic NeoplasmsDesmocollinsGlycoproteinsHT29 CellsHumansMicroscopy, ConfocalPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseTandem Mass SpectrometryAntibodies, MonoclonalAntigens, Tumor-Associated, CarbohydrateDesmocollinsGlycoproteinsPeptide-N4-(N-acetyl-beta-glucosaminyl) Asparagine AmidaseTn antigenanti-Tn antigencolon cancerDesmocollindesmosomegrowth inhibitory mAbMLS128receptor

Identifiers

PMID31168022
PMCPMC8219476
OpenAlexW2948325164

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.